Zynerba Pharmaceuticals, Inc.’s $50.4 Million Public Offering of Common Shares

Hogan Lovells is representing Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, in a public offering worth approximately US$50.4 million.

The offering of 2.8 million shares of its common stock at a price of US$18.00 per share is subject to customary closing conditions. Proceeds will be used to fund research, clinical development and general corporate purposes. The transaction is expected to close on or about January 24, 2017.

The Hogan Lovells team included Rachael Bushey (Picture), Jennifer Porter, and D. Taylor Ocasio. Susan Lee provided regulatory advice.

Involved fees earner: Rachael Bushey – Hogan Lovells; Jennifer Porter – Hogan Lovells; Taylor Ocasio – Hogan Lovells; Susan Lee – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Zynerba Pharmaceuticals, Inc.;


Author: Ambrogio Visconti